covid-19
The CoroVaxG.3 vaccine, developed by researchers from the Leloir Institute Foundation (FIL) and the state Council for Scientific and Technical Research (CONICET) has been tested in animals in preclinical studies. It will now seek to move towards a human clinical trial.
Reuters
Argentine scientists developed a vaccine dose the only one against Covid-19 that could neutralize the Alpha, Gamma and Delta variants, according to a study published in the journal Vaccines that was released on Friday.
The CoroVaxG.3 vaccine , developed by researchers from the Leloir Institute Foundation (FIL) and the State Council for Scientific and Technical Research (CONICET) has been tested on animals in preclinical studies. It will now seek to move towards a clinical trial in humans.
“The results obtained in preclinical studies move us to move rapidly towards the approval by the regulatory bodies of a clinical trial (in human volunteers)” said Osvaldo Podhajcer, project coordinator and head of FIL’s Molecular and Cellular Therapy Laboratory.
“As long as the necessary funds are obtained, the expectation is that before late 2021 or early 2022 can begin such studies, “he added in a statement on Friday.
The scientist explained that studies in animals show that a single dose of the vaccine generates a immune response of both antibodies and Memory cells against SARS-CoV-2 very powerful that does not decay in 5 months and that claim to extend immunity up to 12 months.
“Due to its potency, we hope that the vaccine not only can it be used as the only dose that protects at least 12 months, but also the dose is lower than that used in current vaccines, in order to make its production at scale more efficient “, indicated Podhajcer.
CoroVaxG.3 is based on a platform of adenovirus non-replicative, totally innocuous, of the type of the vaccines produced by Janssen, Astra Zeneca, CanSino and Gamaleya (Sputnik V), the statement reported.
” However, it is not the same since it is a hybrid adenoviral vector . Our vaccine has been shown in animals to be more potent than versions similar to those circulating on the market and that we developed in our laboratory to compare them, “said Podhajcer.
The results of the study show that the serum from animals vaccinated with a single dose of CoroVaxG.3 was able to neutralize the variant D614G, circulating in the region.
“These same sera almost completely neutralize the Alpha variant and this neutralization is highly preserved against the variants Gamma and Delta, “said the scientist, who is also a senior researcher at CONICET.
Note: This article has been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here